Shares of OPKO Health (NASDAQ: OPK), a diagnostics and biopharmaceutical company, fell hard today after the company announced a secondary share offering. Investors unhappy about dilution of the value of their shares pushed the stock 14.2% lower on Thursday.
After losing $141 million in the first half of 2019, the company finished June with $111 million in cash on its balance sheet and $68 million of high-interest debt that's due in 2020. That leaves it without a lot of options at the moment. Today the company announced a plan to raise $100 million by creating heaps of new shares that will dilute the shares investors have been holding.
OPKO hasn't announced pricing for its upcoming offering, but the dilution will be significant. The stock has fallen to just $1.63 per share. If it gets lucky and sells 50 million shares at $2 each, the outstanding share count will swell by around 14%.
OPKO announced its impending share offering shortly after announcing success in a non-inferiority test with somatrogon, a once-weekly growth hormone injection for children who don't produce enough on their own. The current standard, Genotropin from Pfizer (NYSE: PFE), is just as effective, but parents need to inject their children every day.
OPKO developed somatrogon in partnership with Pfizer and will receive a tiered royalty percentage that tops out in the mid-20s if it's approved. Somatrogon approval could push this biotech stock much higher in the short term, but anyone hoping the royalties will allow the company to finally stop losing money should prepare for disappointment. In the first half of 2019, Genotropin sales sank 15% to just $232 million.
10 stocks we like better than Opko Health
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Opko Health wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of June 1, 2019
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.